These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32185249)

  • 1. Interferon targeted therapies in systemic lupus erythematosus.
    Misra DP; Negi VS
    Mediterr J Rheumatol; 2017 Mar; 28(1):13-19. PubMed ID: 32185249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferon blockade in systemic lupus erythematosus: where do we stand?
    Lauwerys BR; Ducreux J; Houssiau FA
    Rheumatology (Oxford); 2014 Aug; 53(8):1369-76. PubMed ID: 24344319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
    Kalunian KC
    Lupus; 2016 Sep; 25(10):1097-101. PubMed ID: 27497254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting interferons and their pathways in systemic lupus erythematosus.
    Chasset F; Arnaud L
    Autoimmun Rev; 2018 Jan; 17(1):44-52. PubMed ID: 29108825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.
    Sakata K; Nakayamada S; Miyazaki Y; Kubo S; Ishii A; Nakano K; Tanaka Y
    Front Immunol; 2018; 9():1957. PubMed ID: 30210502
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-interferon alpha treatment in SLE.
    Kirou KA; Gkrouzman E
    Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of
    Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
    Front Immunol; 2019; 10():275. PubMed ID: 30846987
    [No Abstract]   [Full Text] [Related]  

  • 8. Predominant Role of Plasmacytoid Dendritic Cells in Stimulating Systemic Autoimmunity.
    Huang X; Dorta-Estremera S; Yao Y; Shen N; Cao W
    Front Immunol; 2015; 6():526. PubMed ID: 26528288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications.
    Xourgia E; Tektonidou MG
    J Autoimmun; 2019 Nov; 104():102311. PubMed ID: 31378637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The central role of dendritic cells and interferon-alpha in SLE.
    Pascual V; Banchereau J; Palucka AK
    Curr Opin Rheumatol; 2003 Sep; 15(5):548-56. PubMed ID: 12960479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α production.
    Zhan Y; Carrington EM; Ko HJ; Vikstrom IB; Oon S; Zhang JG; Vremec D; Brady JL; Bouillet P; Wu L; Huang DC; Wicks IP; Morand EF; Strasser A; Lew AM
    Arthritis Rheumatol; 2015 Mar; 67(3):797-808. PubMed ID: 25418983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus.
    Kim JM; Park SH; Kim HY; Kwok SK
    Int J Mol Sci; 2015 Jun; 16(6):14158-70. PubMed ID: 26110387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon α-targeted therapy.
    Hanaoka H; Takeuchi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):181-8. PubMed ID: 23994795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus.
    Blomberg S; Eloranta ML; Magnusson M; Alm GV; Rönnblom L
    Arthritis Rheum; 2003 Sep; 48(9):2524-32. PubMed ID: 13130472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
    McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
    Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting interferons in systemic lupus erythematosus: current and future prospects.
    Mathian A; Hie M; Cohen-Aubart F; Amoura Z
    Drugs; 2015 May; 75(8):835-46. PubMed ID: 25940912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline.
    Mok CC
    Drugs; 2023 Apr; 83(6):479-496. PubMed ID: 36972009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.